Delivery of intraocular triamcinolone acetonide in the treatment of macular edema

5Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Macular edema (ME) is one of the eventual outcomes of various intraocular and systemic pathologies. The pathogenesis for ME is not yet entirely understood; however, some of the common risk factors for its development have been identified. While this investigation will not discuss the numerous etiologies of ME in detail, it appraises the two most widely studied delivery modalities of intraocular corticosteroids in the treatment of ME-intravitreal injection (IVI) and sub-Tenon's infusion (STI). A thorough review of the medical literature was conducted to identify the efficacy and safety of IVI and STI, specifically for the administration of triamcinolone acetonide (TA), in the setting of ME in an attempt to elucidate a preferred steroid delivery modality for treatment of ME. © 2012 by the authors.

Cite

CITATION STYLE

APA

Pickrell, A., Harris, A., Ngo, S., Amireskandari, A., Stewart, E., & Siesky, B. (2012, March). Delivery of intraocular triamcinolone acetonide in the treatment of macular edema. Pharmaceutics. https://doi.org/10.3390/pharmaceutics4010230

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free